BRAF and Ehlers-Danlos syndrome, musculocontractural type: BRAF/MEK inhibitor combinations (dabrafenib/trametinib) are approved for BRAFV600E-mutated ATCs and have significantly enhanced survival and has high treatment response (overall response rate [ORR] 69%) (10,11).